Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK cell against Ewing sarcoma

新型免疫调节和促进“抑制证明”CAR NK 细胞对抗尤文肉瘤

基本信息

批准号：
10834579
负责人：
TIMOTHY P CRIPE
金额：
$ 25.37万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10834579
关键词：
Address Adoptive Immunotherapy Adoptive Transfer Adult Antigens Binding Biological Products Cancer Burden Cancer Model Case Study Cell surface Cells Childhood Childhood Solid Neoplasm Clinical Clinical Trials Combination immunotherapy Complement Cytometry Data Data Set Development Drug Modulation Effectiveness Ewings sarcoma Funding Future Genomic approach Genomics Goals Homing Hybrids Immune Immune response Immunologic Adjuvants Immunologic Monitoring Immunotherapy Inflammatory Innate Immune Response Interruption Knowledge Macrophage Malignant Childhood Neoplasm Malignant Neoplasms Mediating Minnesota Modality Mutation Myeloid-derived suppressor cells Natural Immunity Natural Killer Cells New York Normal Cell Ohio Oncolytic viruses Patients Pediatric Hospitals Physicians Pre-Clinical Model Proteins Regimen Research Personnel Resistance Resource Sharing STAT3 gene Scientist Signal Transduction Site Solid Neoplasm Source T cell response Technology Testing Therapeutic Traction Transforming Growth Factor beta Tumor Immunity Universities Virotherapy Virus Virus Diseases adaptive immunity anti-tumor immune response cancer cell cancer immunotherapeutics cancer immunotherapy chemokine chemoradiation chimeric antigen receptor chimeric antigen receptor T cells combinatorial conventional therapy cytokine data integration effective therapy embryo/fetus antigen experience immune cell checkpoints immunogenicity immunoregulation immunotherapy clinical trials improved innate immune mechanisms medical schools neoantigens novel oncolytic virotherapy pharmacologic pre-clinical rational design resistance mechanism response small molecule success synergism trafficking transcriptomics translational study tumor tumor microenvironment tumor-immune system interactions

项目摘要

Overall Center Abstract This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to further enable adaptive/hybrid immune approaches. Our aims are to (1) Identify and overcome barriers to utilizing NK and CAR-NK cells as cancer therapeutics, (2) break tolerance to “self” cancer-associated proteins and (3) enhance immunotherapies by targeting suppressive myeloid cells. We will accomplish our aims through four projects, based at two major sites based in Ohio (Nationwide Children’s Hospital) and New York (New York Medical College) with subsites in Columbus (The Ohio State University) and Minneapolis (Univeristy of Minnesota). In addition to an Administrative Shared Resource (Core A, directed by Dr. Timothy Cripe and Associate Director Dr. Mitchell Cairo), the projects are scientifically supported by a comprehensive Genomics & Immune Monitoring Shared Resource (Core B, directed by Dr. Elaine Mardis with several subspecialy assistant directors). Core B provides integrated datasets via state- of-the-art technologies including mass cytometry, single cell transcriptomics, and an array of other genomics approaches that enable detailed characterizations and tracking of cancer cell immunogenicity, the tumor immune microenvironment, and immunologic responses. We have also assembled strong external and internal scientific advisory boards of renowned leaders whose expertise spans the projects and shared resources. The projects are highly integrated and cross-informative. We propose that therapeutic regimens that combine modalities will produce synergy that drives anti-tumor immune responses in preclinical pediatric cancer models, overcoming the limitations of low mutational burdens. Our goal is to generate a sufficient body of knowledge with compelling data to inform the rational design of future clinical trials and thereby improve the lives of children with cancer. 1

总体中心摘要此应用程序描述了儿科俄亥俄-纽约癌症 (Peds-ONC) 免疫治疗中心，该中心创建于对 RFA 的响应是儿科免疫疗法发现和开发的第二个巢穴联盟 (PI-DDN)。主要是对 PI-DDN 资助的 U54（Maris 和 Mackall，MPI）进行补充。我们建议，寻求利用适应性免疫来进一步开发针对新发现抗原的 CAR-T 细胞利用先天免疫来针对儿科癌症，规避对传统疗法的耐药性，并进一步实现适应性/混合免疫方法。我们的目标是 (1) 识别并克服利用 NK 和 CAR-NK 细胞作为癌症疗法的障碍，(2) 打破对“自身”癌症相关蛋白的耐受性，以及（3）通过靶向抑制来增强免疫治疗我们将通过位于俄亥俄州两个主要基地的四个项目来实现我们的目标。（全国儿童医院）和纽约（纽约医学院）在哥伦布（The 俄亥俄州立大学）和明尼阿波利斯大学（明尼苏达大学）此外还有行政共享。资源（核心 A，由 Timothy Cripe 博士和副主任 Mitchell Cairo 博士指导），项目是由综合基因组学和免疫监测共享资源（核心 B，指导）提供科学支持由 Elaine Mardis 博士和几位专科助理主任负责 Core B 通过国家提供综合数据集。最先进的技术，包括质谱流式分析、单细胞转录组学和一系列其他基因组学能够详细表征和跟踪癌细胞免疫原性、肿瘤免疫的方法我们还聚集了强大的外部和内部科学。由知名领导者组成的顾问委员会，其专业知识涵盖项目和共享资源。我们建议结合各种方式的治疗方案将具有高度综合性和交叉信息性。产生协同作用，在临床前儿科癌症模型中驱动抗肿瘤免疫反应，克服我们的目标是产生足够的、具有说服力的知识体系。数据为未来临床试验的合理设计提供信息，从而改善癌症儿童的生活。 1